A longitudinal study of people with autosomal dominant Alzheimer’s disease shows that β-amyloid deposition begins well before neurodegeneration and cognitive decline.
Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.
Marked reductions in cognitive performance are present up to 18 years before people develop Alzheimer’s disease dementia, research shows.
Almost half of patients with bipolar disorder will have comorbid anxiety disorder in their lifetime, show the findings of a systematic review and meta-analysis.
The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.
Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.
Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.
A study comparing outcomes among patients treated with first-line lorazepam, midazolam or clonazepam for status epilepticus finds that the three drugs are broadly equivalent.
Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy.
Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.